Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-DLL-3 CAR-T cells LB2102

A preparation of autologous T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), with potential immunomodulating and antineoplastic activities. Upon administration, autologous anti-DLL3 CAR-T cells LB2102 recognize and induce selective toxicity in DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-DLL3 CAR T cells LB2102
autologous DLL3-directed CAR T cells LB2102
Code name:LB 2102
LB-2102
LB2102
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search